Vitex to Report First Quarter 2005 Financial Results

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Vitex to Report First Quarter 2005 Financial Results
    WATERTOWN, Mass., May 6 /PRNewswire-FirstCall/ -- V.I. Technologies, Inc.
(Nasdaq: VITX) ("Vitex" or "the Company") announced today that the Company
will report its first quarter 2005 financial results on Wednesday, May 11,
2005, at 7:00 a.m. Eastern time, and hold a conference call at 8:30 a.m.
Eastern time to discuss the results.  Dr. Samuel K. Ackerman, Chairman and
CEO, and Mr. John R. Barr, President, will lead the call.

     Date:     Wednesday, May 11, 2005
     Time:     8:30 a.m. Eastern time

     Conference call numbers
     Domestic: (800) 540-0559
     International: (785) 832-1508

    Please call between 8:20 and 8:25 a.m. and ask to be connected to the
Vitex conference call.  A replay of the conference call will be available
until Friday, May 13, 2005, and can be accessed by dialing toll-free (800)
938-1594, and outside the U.S. (402) 220-1543.

    About Vitex
    Vitex is developing the next generation of anti-infective products. The
Company is engaged in the discovery and development of small molecule oral
drugs for the treatment of HIV and other major human viral diseases. Vitex's
proprietary discovery technologies and lead therapeutic candidate PA-457 focus
on novel targets in the virus life cycle, including virus fusion and virus
maturation. The Company's separate INACTINE(TM) technology is designed to
inactivate a wide range of viruses, bacteria and parasites in blood products,
and has demonstrated its ability to remove prion proteins.  For more
information on Vitex, please visit our web site at:
http://www.vitechnologies.com.
    Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, such as the Company's ability to
execute plans to resume its clinical trial program for its lead product
candidate, the INACTINE(TM) viral inactivation system for red blood cells, the
execution of the Company's financing plans, anticipated future clinical trial
timelines or results, the timely availability of new products, market
acceptance of the Company's products, the impacts of competitive products and
pricing, government regulation of the Company's products, the Company's
ability to complete product development collaborations and other strategic
transactions and other risks and uncertainties set forth in the Company's
filings with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from any
forward-looking statements made herein.

    CONTACT:
     John R. Barr
     President
     617-926-1551
     john.barr@vitechnologies.com
SOURCE V.I. Technologies, Inc.
http://www.vitechnologies.com
CONTACT:
John R. Barr, President of V.I. Technologies,
Inc., +1-617-926- 1551, john.barr@vitechnologies.com